Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 234.84 | -1.28% | -3.04 |
Earnings due: Aug 1
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Oversold Stochastic | Weakness | 0.00% | |
Shooting Star Candlestick | Bearish | -1.28% | |
Stochastic Buy Signal | Bullish | -1.28% | |
Oversold Stochastic | Weakness | -1.28% | |
Bullish Engulfing | Bullish | -0.69% | |
Oversold Stochastic | Weakness | -0.69% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 0.23% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.23% | |
Oversold Stochastic | Weakness | 0.23% | |
Oversold Stochastic | Weakness | -0.32% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 11 hours ago |
10 DMA Resistance | about 14 hours ago |
Up 1% | about 14 hours ago |
Shooting Star Candlestick Entry | about 15 hours ago |
Fell Below Previous Day's Low | about 15 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/01/2024
Alnylam Pharmaceuticals, Inc. Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development IBD 50 Cholesterol Liver Disease Amyloid Amyloidosis Huntington's Disease Hemoglobin Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Hemoglobinopathies Monsanto
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 263.73 |
52 Week Low | 141.975 |
Average Volume | 1,152,869 |
200-Day Moving Average | 172.44 |
50-Day Moving Average | 196.94 |
20-Day Moving Average | 246.12 |
10-Day Moving Average | 239.96 |
Average True Range | 7.73 |
RSI (14) | 56.71 |
ADX | 40.6 |
+DI | 28.21 |
-DI | 21.56 |
Chandelier Exit (Long, 3 ATRs) | 240.55 |
Chandelier Exit (Short, 3 ATRs) | 254.19 |
Upper Bollinger Bands | 264.11 |
Lower Bollinger Band | 228.13 |
Percent B (%b) | 0.19 |
BandWidth | 14.62 |
MACD Line | 9.86 |
MACD Signal Line | 15.07 |
MACD Histogram | -5.2158 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 245.18 | ||||
Resistance 3 (R3) | 245.85 | 243.08 | 243.45 | ||
Resistance 2 (R2) | 243.08 | 240.45 | 242.74 | 242.88 | |
Resistance 1 (R1) | 238.96 | 238.82 | 237.58 | 238.29 | 242.30 |
Pivot Point | 236.19 | 236.19 | 235.50 | 235.85 | 236.19 |
Support 1 (S1) | 232.07 | 233.56 | 230.69 | 231.40 | 227.38 |
Support 2 (S2) | 229.30 | 231.93 | 228.96 | 226.80 | |
Support 3 (S3) | 225.18 | 229.30 | 226.23 | ||
Support 4 (S4) | 224.51 |